iBio, Inc. (IBIO) · Nov 20, 2026 · Delisting

iBio delisting notice gives it 180 days to fix $1 bid

Bid-price deficiency — Below $1.00 for 30 consecutive business days; cure deadline May 18, 2027

iBio’s delisting notice flags a sub-$1 bid price, giving the clinical-stage biotech 180 days to regain Nasdaq compliance or pursue a reverse split.

iBio is a clinical-stage AI biotech transitioning from discovery into human testing, with IBIO-600 in a Phase 1 trial and additional obesity and cardiometabolic programs still preclinical. The filing adds a real corporate constraint, not an operating milestone: Nasdaq says iBio failed to maintain the required $1.00 closing bid price for 30 consecutive business days, while the shares remain listed and trading for now.

The immediate consequence is time, not delisting: iBio has until May 18, 2027 to close at or above $1.00 for at least 10 consecutive business days. If it cannot, it may seek a second 180-day period, but that depends on meeting other Nasdaq standards and could require a reverse stock split. 〔0〕

This weakens the current story modestly because it introduces financing and capital-structure friction: maintaining a Nasdaq listing may require a reverse split, which would change the share count and price mechanics without improving the underlying drug pipeline. The filing does not signal a clinical setback or cash crisis; it signals that the market’s current valuation has created a listing problem the company must solve while advancing its programs. 〔1〕

Bottom line: This does not overturn iBio’s drug-development story, but it adds a meaningful execution risk: the company must restore its bid price or potentially restructure its share count to remain on Nasdaq.

What to watch next

Bid-price compliance or reverse-split decision by May 18, 2027

Original filing on SEC EDGAR

More iBio, Inc. news

iBio delisting notice gives it 180 days to fix $1 bid | IBIO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.